Artiva Biotherapeutics: Results Of Operations And Financial Condition, Financial Statements And Exhibits

Item 2.02 Results of Operations and Financial Condition. On November 12, 2024, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, regardless of any general incorporation language in any such filing, unless Artiva expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated November 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Artiva Biotherapeutics, Inc. By: /s/ Fred Aslan Fred Aslan, M.D. President and Chief Executive Officer Dated: November 12, 2024

Artiva Biotherapeutics: Results Of Operations And Financial Condition, Financial Statements And Exhibits

Şirketle ilgili diğer haberler